176 related articles for article (PubMed ID: 36772966)
1. Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53.
Scarpetti L; Oturkar CC; Juric D; Shellock M; Malvarosa G; Post K; Isakoff S; Wang N; Nahed B; Oh K; Das GM; Bardia A
Oncologist; 2023 Apr; 28(4):358-363. PubMed ID: 36772966
[TBL] [Abstract][Full Text] [Related]
2. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
Mishra AK; Abrahamsson A; Dabrosin C
Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
Anestis A; Sarantis P; Theocharis S; Zoi I; Tryfonopoulos D; Korogiannos A; Koumarianou A; Xingi E; Thomaidou D; Kontos M; Papavassiliou AG; Karamouzis MV
J Cancer Res Clin Oncol; 2019 May; 145(5):1221-1233. PubMed ID: 30805773
[TBL] [Abstract][Full Text] [Related]
4. ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer.
Reese JM; Suman VJ; Subramaniam M; Wu X; Negron V; Gingery A; Pitel KS; Shah SS; Cunliffe HE; McCullough AE; Pockaj BA; Couch FJ; Olson JE; Reynolds C; Lingle WL; Spelsberg TC; Goetz MP; Ingle JN; Hawse JR
BMC Cancer; 2014 Oct; 14():749. PubMed ID: 25288324
[TBL] [Abstract][Full Text] [Related]
5. TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer.
Mukhopadhyay UK; Oturkar CC; Adams C; Wickramasekera N; Bansal S; Medisetty R; Miller A; Swetzig WM; Silwal-Pandit L; Børresen-Dale AL; Creighton CJ; Park JH; Konduri SD; Mukhopadhyay A; Caradori A; Omilian A; Bshara W; Kaipparettu BA; Das GM
J Natl Cancer Inst; 2019 Nov; 111(11):1202-1215. PubMed ID: 30990221
[TBL] [Abstract][Full Text] [Related]
6. ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function.
Bado I; Nikolos F; Rajapaksa G; Gustafsson JÅ; Thomas C
Oncotarget; 2016 Mar; 7(12):13599-611. PubMed ID: 26871946
[TBL] [Abstract][Full Text] [Related]
7. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
[TBL] [Abstract][Full Text] [Related]
8. Suppression of G Protein-coupled Estrogen Receptor 1 (GPER1) Enhances the Anti-invasive Efficacy of Selective ERβ Agonists.
Schmitz V; Bauerschmitz G; Gallwas J; Gründker C
Anticancer Res; 2022 Nov; 42(11):5187-5194. PubMed ID: 36288854
[TBL] [Abstract][Full Text] [Related]
9. Estrogen Receptor Beta 1: A Potential Therapeutic Target for Female Triple Negative Breast Cancer.
Dey P; Wang A; Ziegler Y; Kumar S; Yan S; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS
Endocrinology; 2022 Oct; 163(12):. PubMed ID: 36251879
[TBL] [Abstract][Full Text] [Related]
10. Small Non-Coding RNA Profiling Identifies miR-181a-5p as a Mediator of Estrogen Receptor Beta-Induced Inhibition of Cholesterol Biosynthesis in Triple-Negative Breast Cancer.
Alexandrova E; Lamberti J; Saggese P; Pecoraro G; Memoli D; Cappa VM; Ravo M; Iorio R; Tarallo R; Rizzo F; Collina F; Cantile M; Bonito MD; Botti G; Nassa G; Weisz A; Giurato G
Cells; 2020 Apr; 9(4):. PubMed ID: 32260128
[TBL] [Abstract][Full Text] [Related]
11. Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer.
Yan S; Dey P; Ziegler Y; Jiao X; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS
Breast Cancer Res Treat; 2021 Jan; 185(2):281-292. PubMed ID: 33001337
[TBL] [Abstract][Full Text] [Related]
12. Modulation of Mitochondrial ERβ Expression Inhibits Triple-Negative Breast Cancer Tumor Progression by Activating Mitochondrial Function.
Song IS; Jeong YJ; Jeong SH; Kim JE; Han J; Kim TH; Jang SW
Cell Physiol Biochem; 2019; 52(3):468-485. PubMed ID: 30873822
[TBL] [Abstract][Full Text] [Related]
13. Interaction Proteomics Identifies ERbeta Association with Chromatin Repressive Complexes to Inhibit Cholesterol Biosynthesis and Exert An Oncosuppressive Role in Triple-negative Breast Cancer.
Alexandrova E; Giurato G; Saggese P; Pecoraro G; Lamberti J; Ravo M; Rizzo F; Rocco D; Tarallo R; Nyman TA; Collina F; Cantile M; Di Bonito M; Botti G; Nassa G; Weisz A
Mol Cell Proteomics; 2020 Feb; 19(2):245-260. PubMed ID: 31792072
[TBL] [Abstract][Full Text] [Related]
14. Drivers and suppressors of triple-negative breast cancer.
Wu W; Warner M; Wang L; He WW; Zhao R; Guan X; Botero C; Huang B; Ion C; Coombes C; Gustafsson JA
Proc Natl Acad Sci U S A; 2021 Aug; 118(33):. PubMed ID: 34389675
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells.
Hinsche O; Girgert R; Emons G; Gründker C
Int J Oncol; 2015 Feb; 46(2):878-84. PubMed ID: 25420519
[TBL] [Abstract][Full Text] [Related]
16. Estrogen Receptor β as a Therapeutic Target in Breast Cancer Stem Cells.
Ma R; Karthik GM; Lövrot J; Haglund F; Rosin G; Katchy A; Zhang X; Viberg L; Frisell J; Williams C; Linder S; Fredriksson I; Hartman J
J Natl Cancer Inst; 2017 Mar; 109(3):1-14. PubMed ID: 28376210
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen.
Wu X; Subramaniam M; Grygo SB; Sun Z; Negron V; Lingle WL; Goetz MP; Ingle JN; Spelsberg TC; Hawse JR
Breast Cancer Res; 2011 Mar; 13(2):R27. PubMed ID: 21392396
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic restoration and activation of ERβ: an inspiring approach for treatment of triple-negative breast cancer.
Salahuddin A; Ghanem H; Omran GA; Helmy MW
Med Oncol; 2022 Jul; 39(10):150. PubMed ID: 35843988
[TBL] [Abstract][Full Text] [Related]
19. Characteristics, behaviour and role of biomarkers in metastatic triple-negative breast cancer.
Goto Y; Thike AA; Ong CCH; Lim JX; Md Nasir ND; Li H; Koh VCY; Chen XY; Yeong JPS; Sasano H; Tan PH
J Clin Pathol; 2020 Mar; 73(3):147-153. PubMed ID: 31563883
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of PTEN decreases expression of estrogen receptor β and tamoxifen sensitivity of human breast cancer cells.
Treeck O; Schüler-Toprak S; Skrzypczak M; Weber F; Ortmann O
Steroids; 2020 Jan; 153():108521. PubMed ID: 31604073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
